Literature DB >> 24422778

Is haemorrhoidectomy in inflammatory bowel disease harmful? An old dogma re-examined.

N Cracco1, R Zinicola.   

Abstract

AIM: Haemorrhoidectomy and removal of anal skin tags in inflammatory bowel disease (IBD) have been considered to be potentially harmful, but the evidence for this is poor. A review of the literature was undertaken to determine the complications rate after haemorrhoidectomy in patients with IBD.
METHOD: A Medline, PubMed and Cochrane Library search was performed to retrieve studies reporting the surgical treatment of haemorrhoids in patients with IBD. All studies that investigated the complications of haemorrhoidectomy and skin tag removal in patients with IBD were included. Complications included local sepsis, fissure, ulcer, stenosis, faecal incontinence and the direct need for proctectomy or a stoma.
RESULTS: Eleven retrospective studies including 135 patients were identified. Most series were small and lacked information on the interval between surgery and the onset of complications. The range of complications ranged from 0% to 100%. Taking the studies together, complications occurred more frequently in Crohn's disease (CD) (17.1%) than in ulcerative colitis (UC) (5.5%). The risk of complication was much higher in patients with unknown than in those with known diagnosis of IBD (50% vs 9.8% in CD; 9.1% vs 4% in UC).
CONCLUSION: There is great variation in the incidence of complications reported after haemorrhoidectomy or removal of skin tags in patients with IBD and it is not possible to draw a firm conclusion. Nevertheless the incidence of complications is high in patients with CD. Colorectal Disease
© 2014 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  Crohn's disease; Haemorrhoidectomy; complications; perianal Crohn's disease; proctectomy; ulcerative colitis

Mesh:

Year:  2014        PMID: 24422778     DOI: 10.1111/codi.12555

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  5 in total

Review 1.  Management of Complex Anorectal and Perianal Crohn's Disease.

Authors:  Vladimir Bolshinsky; James Church
Journal:  Clin Colon Rectal Surg       Date:  2019-07-02

Review 2.  Anorectal emergencies: WSES-AAST guidelines.

Authors:  Antonio Tarasconi; Gennaro Perrone; Justin Davies; Raul Coimbra; Ernest Moore; Francesco Azzaroli; Hariscine Abongwa; Belinda De Simone; Gaetano Gallo; Giorgio Rossi; Fikri Abu-Zidan; Vanni Agnoletti; Gianluigi de'Angelis; Nicola de'Angelis; Luca Ansaloni; Gian Luca Baiocchi; Paolo Carcoforo; Marco Ceresoli; Alain Chichom-Mefire; Salomone Di Saverio; Federica Gaiani; Mario Giuffrida; Andreas Hecker; Kenji Inaba; Michael Kelly; Andrew Kirkpatrick; Yoram Kluger; Ari Leppäniemi; Andrey Litvin; Carlos Ordoñez; Vittoria Pattonieri; Andrew Peitzman; Manos Pikoulis; Boris Sakakushev; Massimo Sartelli; Vishal Shelat; Edward Tan; Mario Testini; George Velmahos; Imtiaz Wani; Dieter Weber; Walter Biffl; Federico Coccolini; Fausto Catena
Journal:  World J Emerg Surg       Date:  2021-09-16       Impact factor: 5.469

Review 3.  Recent developments in the surgical management of perianal fistula for Crohn's disease.

Authors:  Cristina B Geltzeiler; Nicole Wieghard; Vassiliki L Tsikitis
Journal:  Ann Gastroenterol       Date:  2014

Review 4.  Consensus statement of the Italian society of colorectal surgery (SICCR): management and treatment of hemorrhoidal disease.

Authors:  G Gallo; J Martellucci; A Sturiale; G Clerico; G Milito; F Marino; G Cocorullo; P Giordano; M Mistrangelo; M Trompetto
Journal:  Tech Coloproctol       Date:  2020-01-28       Impact factor: 3.781

Review 5.  Surgical Management of Hemorrhoidal Disease in Inflammatory Bowel Disease: A Systematic Review with Proportional Meta-Analysis.

Authors:  Ugo Grossi; Gaetano Gallo; Gian Luca Di Tanna; Umberto Bracale; Mattia Ballo; Elisa Galasso; Andrea Kazemi Nava; Martino Zucchella; Francesco Cinetto; Marcello Rattazzi; Carla Felice; Giacomo Zanus
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.